Home207940 • KRX
add
Samsung Biologics Co Ltd
Nakaraang pagsara
₩1,116,000.00
Sakop ng araw
₩1,110,000.00 - ₩1,145,000.00
Sakop ng taon
₩721,000.00 - ₩1,209,000.00
Market cap
79.71T KRW
Average na Volume
76.58K
P/E ratio
73.58
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (KRW) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.26T | 17.04% |
Gastos sa pagpapatakbo | 334.17B | 87.16% |
Net na kita | 321.49B | 10.60% |
Net profit margin | 25.59 | -5.50% |
Kita sa bawat share | 4.52K | 10.60% |
EBITDA | 476.48B | -3.14% |
Aktuwal na % ng binabayarang buwis | 14.04% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (KRW) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 1.33T | -35.26% |
Kabuuang asset | 17.34T | 8.04% |
Kabuuang sagutin | 6.43T | 3.47% |
Kabuuang equity | 10.90T | — |
Natitirang share | 71.17M | — |
Presyo para makapag-book | 7.28 | — |
Return on assets | 4.88% | — |
Return on capital | 6.80% | — |
Cash Flow
Net change in cash
| (KRW) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 321.49B | 10.60% |
Cash mula sa mga operasyon | 389.56B | -53.23% |
Cash mula sa pag-invest | -1.07T | -138.92% |
Cash mula sa financing | 514.35B | 280.15% |
Net change in cash | -149.00B | -267.89% |
Malayang cash flow | -30.00B | -107.16% |
Tungkol
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Itinatag
2011
Website
Mga Empleyado
4,744
